Month: February 2024

OSLO, Norway (5 February 2024) – TGS, a global provider of energy data and intelligence, in a strategic collaboration with SLB, today announced the Engagement 5 Ocean Bottom Node (OBN) multi-client acquisition in the U.S. Gulf of Mexico. Commencing in Q1 2024, the initiation of the seventh program within the seismic joint venture involves the acquisition of 157 OCS blocks [3,650 square kilometers] through a long offset, sparse OBN survey. The expansion of data coverage in the eastern region of Green Canyon will adjoin with prior phases, establishing a continuous coverage area spanning over 23,000 square kilometers from the Mississippi Canyon in the east to Garden Banks in the west. The industry recently participated in the Gulf of Mexico Lease Sale 261, where blocks within the survey area attracted 16 winning bids and a total bid value...

 Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall survival The designation was granted by the U.S. Food and Drug Administration (FDA) based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival with UV1 vaccination as an add-on to ipilimumab and nivolumab immunotherapy UV1 as add-on therapy had previously received Orphan Drug designation for the treatment of mesothelioma and Fast Track designation for unresectable or metastatic melanomaOslo, February 5, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announced that the U.S. Food and Drug Administration (FDA) had granted...

VANCOUVER, British Columbia, Feb. 04, 2024 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (CSE: CLC) (OTCQB: CLCFF) (FRANKFURT:CLB) (the “Company” or “Christina Lake Cannabis” or “CLC”), a leading producer of high quality extracts and sun grown cannabis, is pleased to announce the results of voting at its Annual General and Special Meeting of Shareholders (the “Meeting”) held on February 2, 2024. A total of 69,708,588 common shares were voted at the Meeting, representing 53.16% of the votes attached to all outstanding common shares of the Company. Shareholders voted in favour of all items of business presented at the Meeting, including the re-election of all director nominees as follows: Joel Dumaresq, Salvatore Milia, Nicco Dehaan, Mervin Boychuk, Gil Playford and James McMillan. Shareholders also approved the re-appointment...

BRISBANE, Australia, Feb. 05, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or “the Company”), a leading battery materials and technology company, today announced the appointment of Sharan Burrow AC to its Board of Directors, effective 28 February, 2024. Chairman Robert J. Natter said: “Ms. Burrow is a global leader in creating thriving and diverse workplaces with responsible governance. She is also a sought-after leader in climate action and human rights and will prove invaluable to NOVONIX in our mission to advance clean energy. Ms. Burrow’s involvement in global policy dialogues with United Nations bodies, G7, G20, World Bank, and the International Monetary Fund brings unique expertise to the Board. I am delighted to welcome Ms. Burrow to the NOVONIX Board of Directors, recognizing her...

Figure 1.ELF Score — Change from Baseline at Week 12Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational,...

SHENZHEN, CHINA, Feb. 03, 2024 (GLOBE NEWSWIRE) — China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 2 February 2024, the Group through its wholly-owned subsidiary entered into a Novation Agreement (the “Novation Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“VFMCRP”) and Winhealth Investment (HK) Limited (“Winhealth Investment”) for sucroferric oxyhydroxide chewable tablets Velphoro® (the “Product”). Winhealth Investment and VFMCRP entered into a License Agreement (the “License Agreement”) for the Product on 28 June 2023. In accordance with the License Agreement, Winhealth Investment gained an exclusive license to register，import, promote, distribute, use and sell the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region...

51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden (mean of 10 anti-VEGF injections in preceding 12 months) were randomized to high (3E10 vg/eye) or low (1E10 vg/eye) dose 4D-150 or aflibercept control regimen 4D-150 was well tolerated with a favorable safety profile when evaluated through up to 48 weeks of follow-up: no significant inflammation observed (including no Grade ≥1+ inflammation in high dose patients) and all patients remained off topical steroids High dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through 24 weeks; visual acuity & central subfield thickness were both stable vs. aflibercept Positive interim results...

Subgroup analyses underscore favorable clinical profile and durability of EYP-1901 Presentations highlight previously reported positive Phase 2 DAVIO 2 topline results showing all primary and secondary endpoints were met Results presented today at the Angiogenesis, Exudation, and Degeneration 2024 Virtual MeetingWATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert...

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) — Lancaster Resources Inc. (CSE:LCR | OTCQB:LANRF | FRA:6UF0) (the “Company”) is pleased to announce that it today completed the first tranche of a non-brokered private placement (the “Offering”), previously announced on January 19, 2024 The Company has completed the first tranche of the Offering with the issuance of 2,125,000 units, each consisting of one share and one warrant to purchase one common share at a price of $0.08 for three years after issuance. In connection with the Offering, the Company paid $2,000 in cash commission to a finder and issued finder warrants to purchase 40,000 shares at $0.08 per share for a period of three years. All securities issued...

SURREY, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or the “Company”), TSX.V: AMY, OTCQB: AMYZF, FSE: ID4, hereby announces that Mr. Zarko Meseldzija has resigned from his position on the Board of Directors as of January 21, 2024. As previously communicated, Mr. Meseldzija will continue his association with the Company until March 1, ensuring a smooth transition. About RecycLiCo RecycLiCo Battery Materials Inc. is a battery materials company specializing in sustainable lithium-ion battery recycling and materials production. RecycLiCo has developed advanced technologies that efficiently recover battery-grade materials from lithium-ion batteries, addressing the global demand for environmentally friendly solutions in energy storage. With minimal processing steps and up to 99% extraction...